MEI-HWEI CHANG2021-01-042021-01-0420101089-3261https://www.scopus.com/inward/record.uri?eid=2-s2.0-77954640226&doi=10.1016%2fj.cld.2010.05.010&partnerID=40&md5=43b94d3e7a4c33d7cc832cb0544e1805https://scholars.lib.ntu.edu.tw/handle/123456789/537011Prevention is most cost effective toward successful control of hepatitis B virus (HBV) infection and its complications. It is particularly urgent where HBV infection and hepatocellular carcinoma (HCC) are prevalent. To achieve better results of primary HCC prevention globally, higher world coverage rates of HBV vaccine, better strategies against breakthrough infection/nonresponder, and good long-term protection are needed. With the universal hepatitis B vaccination program starting from neonates in most countries, HBV infection and its complications will be further reduced in this century. An effective decline in the incidence of HCC in adults is expected in the near future. The concept of a cancer preventive vaccine, using HBV as an example, can be applied further to other infectious agents and their related cancers. ? 2010 Elsevier Inc.Hepatitis B immunoglobulin; Hepatitis B surface antigen; Hepatitis B vaccination; Hepatitis B virus; Hepatocellular carcinoma[SDGs]SDG3hepatitis B surface antigen; hepatitis B vaccine; hepatitis B(e) antigen; hepatitis B surface antigen; hepatitis B vaccine; hepatitis B(e) antigen; active immunization; cancer prevention; drug efficacy; hepatitis B; human; humoral immunity; immune response; immunogenicity; immunoprophylaxis; infection control; liver cell carcinoma; nonhuman; passive immunization; patient compliance; review; Taiwan; vaccination; Carcinoma, Hepatocellular; complication; disease management; Disease Outbreaks; drug effects; economics; female; forecasting; hepatitis B; Hepatitis B virus; immunology; Liver Neoplasms; male; newborn; physiology; pregnancy; prevention and control; preventive health service; procedures; trends; vaccination; vertical transmission; Carcinoma, Hepatocellular; Disease Management; Disease Outbreaks; Female; Forecasting; Hepatitis B; Hepatitis B e Antigens; Hepatitis B Surface Antigens; Hepatitis B Vaccines; Hepatitis B virus; Humans; Immunization Programs; Immunization, Passive; Infant, Newborn; Infectious Disease Transmission, Vertical; Liver Neoplasms; Male; Pregnancy; Taiwan; Vaccination; Carcinoma, Hepatocellular; Disease Management; Disease Outbreaks; Female; Forecasting; Hepatitis B; Hepatitis B e Antigens; Hepatitis B Surface Antigens; Hepatitis B Vaccines; Hepatitis B virus; Humans; Immunization Programs; Immunization, Passive; Infant, Newborn; Infectious Disease Transmission, Vertical; Liver Neoplasms; Male; Pregnancy; Taiwan; Vaccinationreview10.1016/j.cld.2010.05.010206380292-s2.0-77954640226